Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at

Stock analysts at started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Rating) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 5.7 %

NYSE BTX opened at $2.55 on Friday. The company has a market cap of $150.01 million, a P/E ratio of -1.12 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The firm has a 50-day simple moving average of $3.20.

Institutional Trading of Brooklyn ImmunoTherapeutics

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC lifted its position in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTXGet Rating) by 20.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,459,626 shares of the company’s stock after acquiring an additional 243,826 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent filing with the Securities and Exchange Commission. 26.00% of the stock is currently owned by institutional investors and hedge funds.

Brooklyn ImmunoTherapeutics Company Profile

(Get Rating)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Featured Stories

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with's FREE daily email newsletter.